| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Istituto Dermopatico dell’Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico, IDI-IRCCS, Rome 00167, Italy [M. G. N., C. L., S. S., E. S., G. R.]; Department of Experimental Medicine and Pathology, University "La Sapienza," Rome 00161, Italy [E. P., A. M. L., C. D. B., A. S.]; Division of Pathology, Azienda Ospedaliera S. Giovanni-Addolorata, Rome 00184, Italy [D. R.]; and Kimmel Cancer Institute and Kimmel Cancer Center, Philadelphia, Pennsylvania 19107 [C. M. C.]
Chromosomal rearrangements observed in T-cell prolymphocytic leukemia involve the translocation of one T-cell receptor gene to either chromosome 14q32 or Xq28, deregulating the expression of cellular proto-oncogenes of unknown function, such as TCL1 or its homologue, MTCP1. In the human hematopoietic system, TCL1 expression is predominantly observed in developing B lymphocytes, whereas its overexpression in T cells causes mature T-cell proliferation in transgenic mice. In this study, using a newly generated monoclonal antibody against recombinant TCL1 protein, we extended our analysis mainly by immunohistochemistry and also by fluorescence-activated cell sorting and Western blot to a large tumor lymphoma data bank including 194 cases of lymphoproliferative disorders of B- and T-cell origin as well as reactive lymphoid tissues. The results obtained show that in reactive lymphoid tissues, TCL1 is strongly expressed by a subset of mantle zone B lymphocytes and is expressed to a lesser extent by follicle center cells and by scattered interfollicular small lymphocytes. In B-cell neoplasia, TCL1 was expressed in the majority of the cases, including lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (60%), and primary cutaneous B cell lymphoma (55%). TCL1 expression was observed in both the cytoplasmic and nuclear compartments, as confirmed by Western blot analysis. Conversely, TCL1 was not expressed in Hodgkin/Reed-Sternberg cells, multiple myelomas, marginal zone B-cell lymphomas, CD30+ anaplastic large cell lymphoma, lymphoblastic T-cell lymphoma, peripheral T-cell lymphoma, and mycosis fungoides. These data indicate that TCL1 is expressed in more differentiated B cells, under both reactive and neoplastic conditions, from antigen committed B cells and in germinal center B cells and is down-regulated in the latest stage of B-cell differentiation.
This article has been cited by other articles:
|
|
 |
|
  M. Herling, K. A. Patel, M. A. Teitell, M. Konopleva, F. Ravandi, R. Kobayashi, and D. Jones High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia Blood, January 1, 2008; 111(1): 328 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noguchi, V. Ropars, C. Roumestand, and F. Suizu Proto-oncogene TCL1: more than just a coactivator for Akt FASEB J, August 1, 2007; 21(10): 2273 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Kuraishy, S. W. French, M. Sherman, M. Herling, D. Jones, R. Wall, and M. A. Teitell TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation PNAS, June 12, 2007; 104(24): 10175 - 10180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hiromura, F. Suizu, M. Narita, K. Kinowaki, and M. Noguchi Identification of Nerve Growth Factor-responsive Element of the TCL1 Promoter as a Novel Negative Regulatory Element J. Biol. Chem., September 22, 2006; 281(38): 27753 - 27764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Shen, D. O. Ferguson, M. Renard, K. K. Hoyer, U. Kim, X. Hao, F. W. Alt, R. G. Roeder, H. C. Morse III, and M. A. Teitell Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation Blood, September 15, 2006; 108(6): 1991 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Koo, I. Sohn, S. Kim, and J. W. Lee Structured polychotomous machine diagnosis of multiple cancer types using gene expression Bioinformatics, April 15, 2006; 22(8): 950 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zanesi, R. Aqeilan, A. Drusco, M. Kaou, C. Sevignani, S. Costinean, L. Bortesi, G. La Rocca, P. Koldovsky, S. Volinia, et al. Effect of Rapamycin on Mouse Chronic Lymphocytic Leukemia and the Development of Nonhematopoietic Malignancies in E{micro}-TCL1 Transgenic Mice Cancer Res., January 15, 2006; 66(2): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Vermi, F. Facchetti, E. Riboldi, H. Heine, S. Scutera, S. Stornello, D. Ravarino, P. Cappello, M. Giovarelli, R. Badolato, et al. Role of dendritic cell-derived CXCL13 in the pathogenesis of Bartonella henselae B-rich granuloma Blood, January 15, 2006; 107(2): 454 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chiorazzi, K. R. Rai, and M. Ferrarini Chronic Lymphocytic Leukemia N. Engl. J. Med., February 24, 2005; 352(8): 804 - 815. [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Kang, M. G. Narducci, C. Lazzeri, A. M. Mongiovi, E. Caprini, A. Bresin, F. Martelli, J. Rothstein, C. M. Croce, M. D. Cooper, et al. Impaired T- and B-cell development in Tcl1-deficient mice Blood, February 1, 2005; 105(3): 1288 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herling, M. A. Teitell, R. R. Shen, L. J. Medeiros, and D. Jones TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin Blood, June 15, 2003; 101(12): 5007 - 5009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kiss, J. Nishikawa, K. Takada, P. Trivedi, G. Klein, and L. Szekely T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus- carrying Burkitt lymphoma lines PNAS, April 15, 2003; 100(8): 4813 - 4818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. French, C. S. Malone, R. R. Shen, M. Renard, S. E. Henson, M. D. Miner, R. Wall, and M. A. Teitell Sp1 Transactivation of the TCL1 Oncogene J. Biol. Chem., January 3, 2003; 278(2): 948 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Hoyer, S. W. French, D. E. Turner, M. T. N. Nguyen, M. Renard, C. S. Malone, S. Knoetig, C.-F. Qi, T. T. Su, H. Cheroutre, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma PNAS, October 29, 2002; 99(22): 14392 - 14397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Narducci, M. T. Fiorenza, S.-M. Kang, A. Bevilacqua, M. Di Giacomo, D. Remotti, M. C. Picchio, V. Fidanza, M. D. Cooper, C. M. Croce, et al. TCL1 participates in early embryonic development and is overexpressed in human seminomas PNAS, September 3, 2002; 99(18): 11712 - 11717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bichi, S. A. Shinton, E. S. Martin, A. Koval, G. A. Calin, R. Cesari, G. Russo, R. R. Hardy, and C. M. Croce Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression PNAS, May 14, 2002; 99(10): 6955 - 6960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kunstle, J. Laine, G. Pierron, S.-i. Kagami, H. Nakajima, F. Hoh, C. Roumestand, M.-H. Stern, and M. Noguchi Identification of Akt Association and Oligomerization Domains of the Akt Kinase Coactivator TCL1 Mol. Cell. Biol., March 1, 2002; 22(5): 1513 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Laine, G. Kunstle, T. Obata, and M. Noguchi Differential Regulation of Akt Kinase Isoforms by the Members of the TCL1 Oncogene Family J. Biol. Chem., January 25, 2002; 277(5): 3743 - 3751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Pekarsky, C. Hallas, and C. M. Croce Molecular Basis of Mature T-Cell Leukemia JAMA, November 14, 2001; 286(18): 2308 - 2314. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
